Table 1.
Analysis of EGFR Expression in Gliomas within the Study Cohort
| WHO diagnosis | All individuals | Males | Females | Median (range) age (years) | Mean ± SEM EGFR IHC score | EGFR data |
EGFR amplification | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative | Weak | Moderate | Strong | |||||||
| Astrocytoma | ||||||||||
| Grade II | 61 (8.1) | 31 (50.8) | 30 (49.2) | 48 (20–81) | 1.5 ± 0.1 | 4 (6.6) | 30 (49.2) | 19 (31.1) | 8 (13.1) | 3 (4.9) |
| Grade III | 64 (8.5) | 39 (60.9) | 25 (39.1) | 56 (22–94) | 2.2 ± 0.1 | 1 (1.6) | 14 (21.9) | 21 (32.8) | 28 (43.8) | 17 (26.6) |
| GBM | 507 (67.6) | 301 (59.4) | 206 (40.6) | 63 (18–89) | 2.4 ± 0.04 | 12 (2.4) | 64 (12.6) | 140 (27.6) | 291 (57.4) | 224 (44.2) |
| Oligodendroglioma | ||||||||||
| Grade II | 84 (11.2) | 46 (54.8) | 38 (45.2) | 42 (19–78) | 1.8 ± 0.09 | 7 (8.3) | 18 (21.4) | 42 (50.0) | 17 (20.2) | 1 (1.2) |
| Grade III | 34 (4.5) | 23 (67.6) | 11 (32.4) | 48 (32–80) | 2.3 ± 0.1 | 0 (0) | 7 (20.6) | 10 (29.4) | 17 (50.0) | 2 (5.9) |
| Total | 750 (100.0) | 440 (58.7) | 310 (41.3) | 59 (18–94) | 2.2 ± 0.03 | 24 (3.2) | 133 (17.7) | 232 (30.9) | 361 (48.1) | 247 (32.9) |
Data are given as number (percentage) unless otherwise indicated. A total of 750 cases of diffusely infiltrative glioma were analyzed prospectively for EGFR expression, EGFR amplification, and 1p/19q codeletion (see Materials and Methods).